Analysis of Comorbidity of the Patients Affected by Staphylococcal Bacteremia/Sepsis in the Last Ten Years

Enra Lukovac, Nada Koluder-Cimic, Meliha Hadzovic-Cengic, Rusmir Baljic, Amir Hadzic, Refet Gojak
Clinic for Infectious diseases, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Corresponding author: Enra Lukovac, MD. Clinic for Infectious diseases Clinical Center University of Sarajevo, Bolnička 25, 71000 Sarajevo, Bosnia and Herzegovina. Phone:+387 33 297 346. E-mail: enra.lukovac@gmail.com

SUMMARY
Introduction: Staphylococcal bacteremia/sepsis is one of the most serious bacterial infections around the world. In individuals with pre-existing diseases, there is always an increased risk of infections occurring due to impaired immune system, a variety of drug therapy, exposure to a diagnostic and therapeutic procedure and frequent hospitalizations.

Objectives: To analyze the prevalence of comorbidity in a patient with the staphylococcal bacteremia/sepsis according to the diagnosis, the site of infection and according to the isolated agent.

Patients and methods: We analyzed the patients affected by the staphylococcal bacteremia/sepsis and treated in the Clinic for Infectious Diseases during a ten-year period.

Results: 87 patients were included, out of whom 20 (23%) with clinical signs of the bacteremia and 67 (77%) of sepsis. In the analyzed sample, in 36 (41.4%) were not registered comorbidity. Hospital infections are represented by the previous antibiotic, corticosteroid and chemotherapy, pressure ulcers, and different implants. In all comorbidity, the most common isolated bacteria was S. aureus primarily strain MSSA followed by MRSA strain which is more frequent in patients who were surgically treated (comorbidity – various implants).

Conclusion: The results suggest the importance of being mindful of the staphylococcal etiology of the bacteremia/sepsis in patients with comorbidities due to the selection of an adequate initial empirical therapy and reducing the risks of the septic shock.

Key words: staphylococcal bacteremia/sepsis, comorbidity.

1. INTRODUCTION
Epidemiology, clinical spectrum and outcome of the staphylococcal bacteremia/sepsis has been modified for years by different factors. In the era of antibiotic clinical course and outcome of this disease is significantly changed. Various studies have proven that the percentage of mortality is still up to 35% in some countries and it is associated with the acute renal failure, respiratory distress, shock and endocarditis (1, 2). Considering the fact that the Staphylococcus aureus bacteremia/sepsis is one of the most serious bacterial infection around the world, its importance is well recognized in developed countries and during the past years much effort was made in monitoring and prevention, especially infections caused by meticillin resistant strains (3, 4).

2. PATIENTS AND METHODS
The study included 87 patients, out of whom 57.5% (50) were men and 42.5% (37) women, age less than one to eighty years. All patients were hospitalized in the Clinic for Infectious Diseases of the Clinical Center of the University of Sarajevo during the period from 01.01.2000. to 01.10.2011.

3. RESULTS
In a community acquired sepsis without comorbidity were 22 patients, with one were 19, and with two 4 patients. In the study group of patients with hospital originated sepsis without comorbidity were 8 patients, with one comorbidity 5, with two 4 and per 1 patients with four and five pre-existing diseases.

The results of the analyzed group of patients with bacteremia showed that the group with outpatient originated infection have a slightly larger number of patients (6) with one comorbidity compared to patients without comorbidity (4), while in the hospital occurred bacteremia the largest number of patients (4) had two comorbidity and (2) patients one and three, while (2) patients had no comorbidity.

Comorbidity related to disease and conditions specified in the table, which existed together with infection S. aureus/S. epidermidis or it is preceded, was registered
The results of the analyzed group of patients with bacteremia showed that the group with outpatient with one comorbidity was 5, with two was 4 and per 1 patients with four and five pre-existing diseases.

In the study group of patients with hospital originated sepsis without comorbidity were 8 patients, originated infection have a slightly larger number of patients (6) with one comorbidity compared to patients without comorbidity (4), while in the hospital occurred bacteremia the largest number of patients (6) had two comorbidity and (2) patients one and three, while (2) patients had no comorbidity.

Figure 2. Histogram of frequency associated diseases (comorbidity) in relation to the place of origin (hospital/outpatient) and diagnosis (sepsis/bacteremia) (0–no comorbidity, 1–one disease ...)

Figure 1. Percentage of comorbidity in patients with the staphylococcal bacteremia/ sepsis

Table 1. Types of diagnosed disease in comorbidity in patients with a diagnosis of bacteremia/sepsis, patients with hospital and outpatient place of infection, to the isolated strain of S.aureus/S.epidermidis from blood culture

| Comorbidity                          | Total | Sepsis | Bacteremia | Hospital inf. | Outpatient inf. | MSSA | MSSE | MRSA | MRSE |
|--------------------------------------|-------|--------|------------|---------------|----------------|------|------|------|------|
| Diabetes mellitus                    | 16    | 5      | 11         | 7             | 9              | 8    | 1    | 5    | 2    |
| Skin diseases                        | 2     | 0      | 2          | 1             | 1              | 2    | 0    | 0    | 0    |
| Systemic diseases                    | 2     | 1      | 1          | 1             | 1              | 1    | 0    | 1    | 0    |
| Neurological diseases                | 12    | 4      | 8          | 5             | 7              | 7    | 1    | 3    | 1    |
| Malignant diseases                   | 3     | 1      | 2          | 1             | 2              | 2    | 0    | 1    | 0    |
| Antibiotic, Corticosteroid, chemo therapy | 16 | 6      | 10         | 13            | 3              | 7    | 2    | 5    | 2    |
| Trauma                               | 9     | 1      | 8          | 4             | 5              | 5    | 1    | 3    | 0    |
| Pressure ulcers                      | 8     | 1      | 7          | 5             | 3              | 4    | 0    | 2    | 2    |
| Damage to the natural heart valves   | 2     | 0      | 2          | 1             | 1              | 1    | 1    | 0    | 0    |
| Artificial heart valves              | 1     | 0      | 1          | 1             | 0              | 1    | 0    | 0    | 0    |
| Various implants                     | 9     | 3      | 6          | 8             | 1              | 2    | 1    | 5    | 1    |

Table 1. Types of diagnosed disease in comorbidity in patients with a diagnosis of bacteremia/sepsis, patients with hospital and outpatient place of infection, to the isolated strain of S.aureus/S.epidermidis from blood culture

in 51 of 87 patients, provided that for some patients at the same time noted two or more diseases/conditions. From the data in the table can be seen that the different diseases or conditions are variously associated with the investigated subcategories (bacteremia/sepsis, hospital/outpatient infection, different strains of S.aureus/S.epidermidis). So for all the investigated comorbidities more frequent was staphylococcal bacteremia rather than staphylococcal sepsis. Outpatient staphylococcal infections are more common in diabetes mellitus, neurological diseases malignant disease, and hospital infection are represented by the previous antibiotic, corticosteroid and chemo therapy, pressure ulcers, and different implants, while the number of patients for the other comorbidities more or less equally distributed between subcategories of hospital and outpatient infections. In all comorbidity most commonly was isolated S. aureus primarily strain MSSA followed by MRSA strain which is more frequent in patients who were surgically treated (comorbidity-various implants).

4. DISCUSSION

Staphylococci primarily the S. aureus and S. epidermidis, are one of the most virulent human pathogens with the possibility of colonization and infection in hospitalized patients with compromised defense capabilities or without, as well as healthy immunocompetent persons in the outpatient setting. In individuals with pre-existing diseases is always an increased risk for occurrence of infections because of damaged immune system, different drug therapies, exposure to diagnostic and therapeutic procedure and more frequent hospitalizations (5,6). Studies Yamada and colleagues (7) and Kempkera and colleagues (8) show that the most common comorbidity associated with staphylococcal infections are malignant diseases, cardiovascular diseases, diabetes mellitus, immunosuppression and in recent years HIV infection. In a study Laupland and colleagues (9) the greatest risk of developing staphylococcal infections were registered in patients on hemodialysis, with transplanted organs, HIV infection, cancer and diabetes. In our study, 58,6% patients have a comorbidity, which corresponds with data from the literature where the staphylococcal infection is usually expected in patients with comorbidity. In the majority of patients 36,8% was found one pre-existing disease. The most common comorbidity registered in our study are consistent with those from the literature. Following methicillin sensitivity was noted that meticillin sensitive strains were represented in the higher percentage compared to meticillin resistant strains which does not mean that the meticillin-sensitive strains are more pathogen but because in our study was greater representation of this strain in the total number of tested samples.
5. CONCLUSION

The results show that patients with comorbidity have a higher prevalence to become sick with the bacteremia/sepsis, especially in hospital settings which suggests the importance of being mindful of the staphylococcal etiology of the bacteremia/sepsis in patients with comorbidities due to the selection of an adequate initial empirical therapy and reducing the risks of the septic shock.

REFERENCES

1. Mandell GL, Bennett JE, Dolin R (eds). Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Elsevier; Churchill Livingstone; 2005: 3661.

2. Nickerson EK, Wuthiekanun V, Wongsvan G, Limmathurosa D, Srissamang P, Mahavanakul W, et al. Factors predicting and reducing mortality in patients with invasive Staphylococcus aureus disease in a developing country. PLoS One. 2009 Aug; 4(8): e6512.

3. Thwaites GE. United Kingdom Clinical Infection Research Group (UKCIRG). The management of Staphylococcus aureus bacteremia in the United Kingdom and Vietnam: a multi-centre evaluation. PLoS One. 2010 Dec; 5(12): e14170.

4. Gosbell IB. Diagnosis and management of catheter-related bloodstream infections due to Staphylococcus aureus. Intern Med J. 2005 Dec; 35 Suppl 2: S45-S62.

5. Nickerson EK, Wuthiekanun V, Wongsvan G, Limmathurosa D, Srissamang P, Mahavanakul W, et al. Factors predicting and reducing mortality in patients with invasive Staphylococcus aureus disease in a developing country. PLoS One. 2009 Aug; 4(8): e6512.

6. Longtin Y, Sudre P, François P, Schrenzel J, Arambruz C, Pastore R, et al. Community-associated methicillin-resistant Staphylococcus aureus risk factors for infection, and long-term follow-up. Clin Microbiol Infect. 2019 Jun; 15(6): 552–559.

7. Yamada K, Yanagihara K, Hara Y, Araki N, Harada Y, Morinaga Y, et al. Clinical features of bacteremia caused by methicillin-resistant Staphylococcus aureus in a tertiary hospital. Tohoku J Exp Med. 2011; 224(1): 61-67.

8. Kempker RR, Farley MM, Ladson JL, Satola S, Ray SM. Association of methicillin-resistant Staphylococcus aureus (MRSA) USA300 genotype with mortality in MRSA bacteremia. J Infect. 2010 Nov; 61(5): 372-381.

9. Laupland KB, Ross T, Gregson DB. Staphylococcus aureus Bloodstream Infections: Risk Factors, Outcomes, and the Influence of Methicillin Resistance in Calgary, Canada, 2000–2006. J Infect Dis. 2008 Aug; 198(S): 336-343.

INSTRUCTIONS FOR THE AUTHORS

All papers need to be sent to: Editorial board of the journal Mat Soc Med, electronically over the web site www.matmed.org and www.avicenapublisher.org. Every article sent to Mat Soc Med gets its number, and author(s) will be notified if their paper is accepted and what is the number of paper. Original paper could not contains more than 3,000 words, Review article more than 4,500 and Case report more than 1,500 words, including References. Every correspondence will use that number. The paper has to be typed on a standard format (A4), leaving margins of at least 3 cm. All materials, including tables and references, have to be typed double-spaced, so that one page has no more than 2000 alphanumerical characters (30 lines) and total number of used words must not to be more than 3,500. Presenting paper depends on its content, but usually it consists of a title page, summary, text references, legends for pictures and pictures, type your paper in MS Word and send it on a desktop or CD-ROM, so that the editing of your paper will be easier.

Every article has to have a title page with a title of no more than 10 words: name(s), last and first of the author(s), name of the institution the author(s) belongs to, abstract with maximum of 45 letters (including space), footnotes(s) with acknowledgments, name of the first author or another person with whom correspondence will be maintained.

The paper needs to contain structured summary, 200 words at the most. Summary needs to hold title, full name(s) and surname(s) of the author(s) and coauthor(s), work institution, and all essential facts of the work, introduction, formulation of problems, purpose of work, used methods, with specific data, if possible) and basic facts. Summary must contain the re-view of underlined data, ideas and conclusions from text. Summary must have no quoted references. Four key words, at the most, need to be placed below the text.

Authentic papers contain these parts: introduction, goal, methods, results, discussion and conclusion. Introduction is brief and clear review of the problem. Methods are shown, so that interested reader is able to repeat described research. Known methods don’t need to be identified, they are cited (referenced). If drugs are listed, their generic name is used, (brand name can be written in brackets). Results need to be shown clearly and logically, and their significance must be proven by statistical analysis. In discussion, results are interpreted and compared to the existing and previously published findings in the same field. Conclusions have to give an answer to author’s goals.

Quoting references must be on a scale, in which they are really used. Quoting most recent literature is recommended. Only published articles, (or articles accepted for publishing), can be used as references. Not published observations and personal notifications need to be in text in brackets. Showing references must be as how they appear in the text. References cited in tables or pictures are also numbered according to the quotation order. All references should be compiled at the end of the article in the Vancouver style or PubMed style (i.e. www scopemed.org).

Tests used for statistical analysis need to be shown in text and in tables or pictures containing statistical analysis.

Tables have to be numbered and shown by their order, so they can be understood without having to read the paper. Every column needs to have a title, every measuring unit (SI) has to be clearly marked (i.e. preferably in footnotes below the table, in Arabic numbers or symbols). Pictures also have to be numbered as they appear in the text. drawings need to be enclosed on a white or tracing paper, while black and white photos have to be printed on a radiator paper. Legends (e.g. next to pictures and photos), have to be written on a separate A4 format paper. All illustrations, (pictures, drawings, diagrams), have to be original, and on their backs contain illustration number, first author’s last name, abbreviated title of the paper and picture at the top. It is appreciated, if author marks the place for the table or picture. Papers could not be submitted with included more of 4 Tables, Figures or Graphs. Every additional must be paid 20 euros each. Use of abbreviations have to be reduced to a minimum. Conventional units can be used without their definitions. Supplement. If papers contain original contribution to a statistical method or author believes, without quoting original computer program, that paper’s value will be reduced. Editorial staff will consider possibility of publishing mathematics /statistic analysis in extension.

Any practice of plagiarism will not be tolerated regarding submitted articles. Non-identifiable quoted parts of the articles from other authors are known act of plagiarism if it is not cited or referencing in appropriate places in the article. Advertent practice of plagiarism will abort reviewing process or article submission. Author(s) may suggest or exclude peer-re viewers for their articles but Editorial Board has the right to reject their opinions or suggestions according to copyright Assignment form signed by authors before reviewing process. Authors must respect guidelines and rules of IcMJE, WAME, CoPE, E A SE, linked on www.avicenapublisher.org. All individuals listed as authors should qualify for authorship and should have participated sufficiently in the work to take public responsibility for appropriate portions of the content and follow the next conditions: a) substantial contributions to the conceptions and design, acquisition of data, or anal- ysis and interpretation of data; b) drafting the article or revising it critically for important intellectual content; c) final approval of the version to be published (all co-authors must sign copyright Assignment form downloaded from www.avicenapublisher.org. All other contributors to the article’s subject who does not qualify for authorship should be listed in acknowledgement section, for all relevant information about authorship follow IcMJE guidelines.

All authors must make a formal statement at the time of submission indicating any potential conflict of interest that might constitute an embarrassment to any of the authors if it were not to be declared and were to emerge after publication. Such conflict of interest might include, but not limited to, share holding in or receipt of grant or consultancy free form a company whose product features in the submitted manuscript or which manufactures a competing product. All authors must submit a statement of conflict of interest to be published at the end of their article (conflict of Interest: non declared).